Clinical trial
Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's…
NCT00020800 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00020800 |
|---|---|
| Title | Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia |
| Official title | Phase II Study of Combination Rituxan (Rituximab, Mabthera) and Fludarabine Therapy in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia) |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | rituximab, fludarabine phosphate |
| Enrollment | 7 |
| Start date | Sep 1, 2001 |
| Primary completion | Apr 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 8, 2013 |
| Countries | Canada, Sweden, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: